<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001117</url>
  </required_header>
  <id_info>
    <org_study_id>52-00001-0000</org_study_id>
    <nct_id>NCT01001117</nct_id>
  </id_info>
  <brief_title>Laser Treatment of the Crystalline Lens</brief_title>
  <official_title>A Prospective Single-Center Clinical Trial to Evaluate the Feasibility of Laser Treatment of the Crystalline Lens in Subjects Having Elected to Undergo Lens Extraction and Intraocular Lens Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LensAR Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LensAR Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of a femtosecond laser in cataract surgery that gives equivalent or improved results&#xD;
      comapred to conventional phaco-emulsification surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the feasibility of the LensAR laser system to&#xD;
      surgically intervene within the crystalline lens. The primary goal of this initial study is&#xD;
      to establish safety parameters as compared with conventional phacoemulsification procedures,&#xD;
      and to evaluate the ability to provide an accurate and consistent anterior capsular opening&#xD;
      (capsulotomy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capsulotomy a. Ease of opening b. Achievement of intended shape and size</measure>
    <time_frame>Time of Surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens removal a. Ease of irrigation / aspiration (time) b. Reduced ultrasound phacoemulsification</measure>
    <time_frame>Time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Posterior capsule rupture &lt; 10% occurrence rate</measure>
    <time_frame>Time of Surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Less than 5% of eyes should lose more than two lines of BSCVA</measure>
    <time_frame>3 months post-operative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Laser treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eye treated with LensAR Laser System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Eye</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contralateral eye treated with conventional phaco-emulsification</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LensAR laser surgery</intervention_name>
    <description>Use of laser for cataract surgery</description>
    <arm_group_label>Laser treated</arm_group_label>
    <other_name>LensAR Laser System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phaco-emulsification cataract surgery</intervention_name>
    <description>Phaco-emulsification cataract surgery</description>
    <arm_group_label>Control Eye</arm_group_label>
    <other_name>Exact equipment varies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must sign and be given a copy of the written informed consent form.&#xD;
&#xD;
          -  Subjects must have elected to undergo lens extraction and foldable monofocal IOL&#xD;
             implantation (ideally of the same type), and then elect to have the LensAR laser&#xD;
             surgery.&#xD;
&#xD;
          -  Subjects must be willing and able to return for scheduled follow-up examinations for a&#xD;
             minimum of 12 months after surgery.&#xD;
&#xD;
          -  Central 8 mm of clear cornea without vascularization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with prior anterior segment or vitreo-retinal surgical intervention in the&#xD;
             eye to be treated.&#xD;
&#xD;
          -  Subjects with lenticular cataracts with nuclear grading greater than Grade 4 on the&#xD;
             LOCS III scale.&#xD;
&#xD;
          -  Subjects who cannot attain ocular dilation of 7.0 mm.&#xD;
&#xD;
          -  Subjects with anterior segment pathology in the eye to be treated that is not directly&#xD;
             improved by lens extraction and IOL implantation.&#xD;
&#xD;
          -  Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease or any&#xD;
             corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal&#xD;
             erosion, etc.) in the eye to be treated.&#xD;
&#xD;
          -  Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye&#xD;
             to be treated.&#xD;
&#xD;
          -  Subjects with a history of severe dry eye not responding to therapy.&#xD;
&#xD;
          -  Subjects with macular degeneration, history of retinal detachment, or any other fundus&#xD;
             findings that would pose a risk to safety or an acceptable visual outcome in the eye&#xD;
             to be treated.&#xD;
&#xD;
          -  Subjects with a history of herpes zoster or herpes simplex keratitis.&#xD;
&#xD;
          -  Subjects who have a history of steroid-responsive rise in intraocular pressure,&#xD;
             glaucoma, or are a glaucoma suspect.&#xD;
&#xD;
          -  Subjects with diabetic retinopathy, autoimmune disease, connective tissue disease,&#xD;
             pseudoexfoliation syndrome, or clinically significant atopic syndrome.&#xD;
&#xD;
          -  Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that&#xD;
             may affect wound healing, and any immuno-compromised subjects.&#xD;
&#xD;
          -  Subjects who are using ophthalmic medication(s) other than artificial tears for&#xD;
             treatment of ocular pathology including ocular allergy.&#xD;
&#xD;
          -  Subjects using systemic medications with significant ocular side effects.&#xD;
&#xD;
          -  Subjects who are pregnant, lactating, or of child-bearing potential and not practicing&#xD;
             a medically approved method of birth control.&#xD;
&#xD;
          -  Subjects with known sensitivity to planned study concomitant medications.&#xD;
&#xD;
          -  Subjects who are participating in any other ophthalmic drug or device clinical trial&#xD;
             during the time of this clinical investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Naranjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociacion Para Evitar La Ceguera en Mexico IAP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge VIllar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociacion Para Evitar La Ceguera en Mexico IAP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociacion Para Evitar La Cuguera en Mexico IAP</name>
      <address>
        <city>Mexico City</city>
        <zip>DF 04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical &amp; Regulatory Affairs</name_title>
    <organization>LensAR Inc</organization>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Capsulotomy</keyword>
  <keyword>Capsulorrhexis</keyword>
  <keyword>Phacoemulsification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

